Loading company
Ardelyx, Inc.
ARDX · Nasdaq · ·
Next earnings: October 29, 2026
$3.39-0.7%Sep 29 close
- 1M
- -11.2%
- 6M
- -39.0%
- 1Y
- -38.6%
- 5Y
- +150.7%
ARDX · Nasdaq · ·
Next earnings: October 29, 2026
$3.39-0.7%Sep 29 close
Ardelyx, Inc. is scheduled to report next on October 29, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $120.9M | $97.7M | +23.77% |
| Profit | -$16.7M | -$19.1M | +12.36% |
| Profit per share | -$0.07 | -$0.08 | +12.50% |
| Free Cash Flow | -$6.4M | -$26M | +75.33% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
“In the second quarter of 2026, we delivered combined revenue of $118 million, up 31% year over year, the largest quarterly revenue in our Company’s history,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
Ardelyx is a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs. Ardelyx has two commercial products approved in the United States, IBSRELA ® (tenapanor) and XPHOZAH ® (tenapanor). The company’s pipeline includes the Phase 3 development of IBSRELA for chronic idiopathic constipation (CIC) and RDX10531, a next-generation NHE3 inhibitor with potential application across multiple therapeutic areas. Ardelyx works with partners to develop and commercialize our products outside of the United States.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Ardelyx, Inc.’s Item 2.02 8-K filed August 6, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Ardelyx, Inc. has no earnings call transcript available.